Amgen stock skidded late Tuesday after the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
Zacks.com on MSN19h
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical HoldAmgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town. Meanwhile, the company on Friday kicked off construction on a second ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback